LivaNova also says data presented at AATS reinforces the Memo 3D ReChord as safe and effective for mitral valve repair procedures
Sutureless surgical aortic valve implantation means quicker procedure with enhanced safety says physician
Major milestone as patients needing open aortic valve replacement benefit from easier-to-implant prosthesis
Sorin’s newly announced study is first international prospective RCT to compare its TAVR offering with traditional replacement valve
Sorin’s Sutureless Valve is in the process of undergoing U.S. FDA approval, but in the meantime is beefing up its international presence with the go-ahed in another market
Sorin’s sutureless aortic valve demonstrates improved outcome compared with TAVR in medium-high risk patients and favorable outcomes in every day surgery
Sorin Group has announced the results of the Perceval CAVALIER Trial and of the Pooled European Multicenter Experience at this week’s 28th EACTS Congress
Italian Cardiovascular device specialist Sorin Group tells us its Perceval™ sutureless aortic valve has received CE mark approval for adult age indication allowing treatment of a wider spectrum of patients with aortic stenosis and/or steno-insufficiency.
Last week we covered the news that Italian cardiovascular outfit Sorin had gained CE mark approval for its Solo Smart stentless heart valve. Now the company tells us it has also gained the European nod for the large sizes of its sutureless Perceval valve.
Sorin has announced CE Mark approval for extended indications of the Perceval™ S sutureless valve, expanding the market and, the company says, paving the way for adoption of Minimally Invasive Cardiac Surgery
Sorin Group announced today the enrolment of the first three patients in a clinical trial aimed at obtaining European market approval for its ‘Perceval S’ Sutureless Aortic Heart Valve.
New data reinforce the clinical value of the Perceval™ Sutureless Valve as a safe and effective bioprosthesis for patients in need of aortic valve replacement
Perceval Sutureless valve is now embarked on 1200 pt worldwide study to compare it with standard sutured valve
Sorin/Cyberonics coming together as LivaNova followed by two valve approvals
Sorin’s financials for 2013 look pretty punchy and despite a few product-lifecycle challenges appear to indicate that the financial impact of the recent earthquake experienced at one of the company’s facilities are well behind it.
Q3 revenues for Sorin are somewhat clouded by last year’s earthquake which saw supply of some of its core lines temporarily suspended. A year later and the Italian cardiac device maker is recovering nicely as revenues return to pre-disaster levels and above.